nach oben

Archivum Immunologiae et Therapiae Experimentalis

Erschienen in:

01.12.2022 | Original Article

Monitoring of Soluble Forms of BAFF System (BAFF, APRIL, sR-BAFF, sTACI and sBCMA) in Kidney Transplantation

verfasst von: Rafael Alfaro, Santiago Llorente, Pedro Martinez, Víctor Jimenez-Coll, Helios Martínez-Banaclocha, José Antonio Galián, Carmen Botella, María Rosa Moya-Quiles, Jesús de la Peña-Moral, Alfredo Minguela, Isabel Legaz, Manuel Muro

Erschienen in: Archivum Immunologiae et Therapiae Experimentalis | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

BAFF system plays an essential role in B cells homeostasis and tolerance, although it has widely not been tested in transplantation with doubtful results. The main purpose was to study the BAFF soluble forms and their correlation with acute rejection (AR) and donor-specific antibodies production. Serum levels of BAFF, APRIL, and soluble forms of their receptors were analyzed in renal recipients with and without acute rejection (AR/NAR) appearance. All molecules were evaluated at pre- and post-transplantation. sTACI showed a significant correlation with BAFF and sR-BAFF levels, and sBCMA also showed a positive correlation with sAPRIL levels. A significant increase in sAPRIL levels in patients suffering AR was also found, and ROC curves analysis showed an AUC = 0.724, a concentration of 6.05 ng/ml (sensitivity: 66.7%; specificity: 73.3%), the best cutoff point for predicting AR. In the post-transplant dynamics of sAPRIL levels in the longitudinal cohort, we observed a significant decrease at 3 and 6 month post-transplantation compared to pretransplantation status. We also observed that recipients with high pre-transplant levels of sAPRIL generated antibodies earlier than those with lower sAPRIL levels, although their long-term post-transplantation was not different. Our results show that elevated serum levels of APRIL may be helpful as a biomarker for the diagnosis of AR, although the longitudinal study shows that it is not helpful as a prognostic biomarker.

Vorheriger Artikel Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model

Nächster Artikel Correction to: CD5L Secreted by Macrophage on Atherosclerosis Progression Based on Lipid Metabolism Induced Inflammatory Damage

Afzali S, Salehi S, Shahi A et al (2021) Investigating the role of BAFF and its receptors in renal transplant recipients with chronic antibody-mediated rejection. J Immunol Res 2021:6654992. https://doi.org/10.1155/2021/6654992CrossRefPubMedPubMedCentral

Alfaro R, Jaouad EKEB, Llorente S et al (2021a) Personalized medicine for kidney transplantation: association of graft survival and acute transplant rejection with genetic variation in B cell activating factor system signaling. OMICS 25:725–737. https://doi.org/10.1089/OMI.2021.0099CrossRefPubMed

Alfaro R, Legaz I, González-Martínez G et al (2021b) Monitoring of B cell in kidney transplantation: development of a novel clusters analysis and role of transitional B cells in transplant outcome. Diagnostics 11:641. https://doi.org/10.3390/diagnostics11040641CrossRefPubMedPubMedCentral

Alfaro R, Legaz I, Jimenez-Coll V et al (2021c) MicroRNA expression changes in kidney transplant: diagnostic efficacy of miR-150-5p as potential rejection biomarker, pilot study. J Clin Med 10:2748. https://doi.org/10.3390/JCM10132748CrossRefPubMedPubMedCentral

Benson MJ, Dillon SR, Castigli E et al (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180:3655–3659. https://doi.org/10.4049/JIMMUNOL.180.6.3655CrossRefPubMed

Bijkerk R, Florijn BW, Khairoun M et al (2017) Acute rejection after kidney transplantation associates with circulating microRNAs and vascular injury. Transpl Direct 3:e174. https://doi.org/10.1097/TXD.0000000000000699CrossRef

Bloom DD, Reshetylo S, Nytes C et al (2018) Blockade of BAFF receptor BR3 on T cells enhances their activation and cytotoxicity. J Immunother 41:213. https://doi.org/10.1097/CJI.0000000000000209CrossRefPubMedPubMedCentral

Bossen C, Schneider P (2006) BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 18:263–275. https://doi.org/10.1016/J.SMIM.2006.04.006CrossRefPubMed

Calame KL (2001) Plasma cells: finding new light at the end of B cell development. Nat Immunol 212(2):1103–1108. https://doi.org/10.1038/ni1201-1103CrossRef

Chasset F, de Masson A, Le Buanec H et al (2016) APRIL levels are associated with disease activity in human chronic graft-versus-host disease. Haematologica 101:e312. https://doi.org/10.3324/HAEMATOL.2016.145409CrossRefPubMedPubMedCentral

Chen M, Lin X, Liu Y et al (2014) The function of BAFF on T helper cells in autoimmunity. Cytokine Growth Factor Rev 25:301. https://doi.org/10.1016/J.CYTOGFR.2013.12.011CrossRefPubMed

Clark WB, Brown-Gentry KD, Crawford DC et al (2011) Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. Blood 118:1140–1144. https://doi.org/10.1182/blood-2010-09-310011CrossRefPubMed

Cohen D, Colvin RB, Daha MR et al (2012) Pros and cons for C4d as a biomarker. Kidney Int 81:628–639. https://pubmed.ncbi.nlm.nih.gov/22297669/.

Darce JR, Arendt BK, Wu X et al (2007) Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 179:7276–7286. https://doi.org/10.4049/jimmunol.179.11.7276CrossRefPubMed

Daridon C, Youinou P, Pers JO (2008) BAFF, APRIL, TWE-PRIL: who’s who? Autoimmun Rev 7:267–271. https://doi.org/10.1016/J.AUTREV.2007.05.002CrossRefPubMed

Davidson A (2010) Targeting BAFF in autoimmunity. Curr Opin Immunol 22:732–739. https://pubmed.ncbi.nlm.nih.gov/20970975/.

Friebus-Kardash J, Wilde B, Keles D et al (2018) Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival. Transpl Immunol 47:10–17. https://doi.org/10.1016/J.TRIM.2017.12.004CrossRefPubMed

Galián JA, Mrowiec A, Muro M (2016) Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and future. Expert Opin Ther Targets 20:859–867. https://doi.org/10.1517/14728222.2016.1135904CrossRefPubMed

Ghermezi M, Li M, Vardanyan S et al (2017) Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica 102:785. https://doi.org/10.3324/HAEMATOL.2016.150896CrossRefPubMedPubMedCentral

Grenzi PC, Campos ÉF, Silva HT et al (2015) Post-transplant soluble CD30 levels are associated with early subclinical rejection in kidney transplantation. Transpl Immunol 32:61–65. https://doi.org/10.1016/J.TRIM.2015.02.004CrossRefPubMed

Gutierrez MJ, Desiderio SV, Wang NY et al (2019) Soluble markers of antibody secreting cell function as predictors of infection risk in rheumatoid arthritis. J Immunol Res 2019:3658215. https://doi.org/10.1155/2019/3658215CrossRefPubMedPubMedCentral

Halloran PF, Halloran PF (2010) T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transpl 10:1126–1134. https://doi.org/10.1111/J.1600-6143.2010.03053.XCrossRef

Harris DP, Haynes L, Sayles PC et al (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1:475–482. https://doi.org/10.1038/82717CrossRefPubMed

Hoffmann FS, Kuhn P-H, Laurent SA et al (2015) The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J Immunol 194:542–552. https://doi.org/10.4049/jimmunol.1402070CrossRefPubMed

Hua C, Audo R, Yeremenko N et al (2016) A proliferation inducing ligand (APRIL) promotes IL-10 production and regulatory functions of human B cells. J Autoimmun 73:64–72. https://doi.org/10.1016/J.JAUT.2016.06.002CrossRefPubMed

Irure-Ventura J, Segundo DS, Rodrigo E et al (2020) High pretransplant BAFF levels and B-cell subset polarized towards a memory phenotype as predictive biomarkers for antibody-mediated rejection. Int J Mol Sci 21:779. https://doi.org/10.3390/IJMS21030779CrossRefPubMedCentral

Jo HA, Han SS, Lee S et al (2019) The association of tumor necrosis factor superfamily 13 with recurrence of immunoglobulin A nephropathy in living related kidney transplantation. BMC Nephrol 20:33. https://doi.org/10.1186/S12882-019-1222-4/FIGURES/2CrossRefPubMedPubMedCentral

Krupa A, Jenkins R, Luo DD et al (2010) Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 21:438–447. https://doi.org/10.1681/ASN.2009050530CrossRefPubMedPubMedCentral

Kwun J, Page E, Hong JJ et al (2015) Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model. Am J Transpl 15:815–822. https://doi.org/10.1111/ajt.13045CrossRef

Laurent SA, Hoffmann FS, Kuhn PH et al (2015) γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 6:7333. https://doi.org/10.1038/ncomms8333CrossRefPubMed

Legaz I, Bernardo MV, Alfaro R et al (2021) PCR array technology in biopsy samples identifies up-regulated mTOR pathway genes as potential rejection biomarkers after kidney transplantation. Front Med 8:547849. https://doi.org/10.3389/fmed.2021.547849CrossRef

Legaz I, Boix F, López M et al (2020) Influence of preformed antibodies in liver transplantation. J Clin Med 9:708. https://doi.org/10.3390/jcm9030708CrossRefPubMedCentral

Luu VP, Vazquez MI, Zlotnik A (2014) B cells participate in tolerance and autoimmunity through cytokine production. Autoimmunity 47:1–12. https://pubmed.ncbi.nlm.nih.gov/24245950/.

Min JW, Kim KW, Kim BM et al (2016) Clinical significance of pre-and post-transplant BAFF levels in kidney transplant recipients. PLoS One 11:e0162964. https://doi.org/10.1371/journal.pone.0162964CrossRefPubMedPubMedCentral

Nafar M, Farrokhi F, Vaezi M et al (2009) Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection. Int Urol Nephrol 41:687–693. https://doi.org/10.1007/S11255-008-9505-X/FIGURES/2CrossRefPubMed

Nelson PJ, Krensky AM (2001) Chemokines, chemokine receptors, and allograft rejection. Immunity 14:377–386. https://pubmed.ncbi.nlm.nih.gov/11336683/.

Newell KA, Asare A, Sanz I et al (2015) Longitudinal studies of a B cell-derived signature of tolerance in renal transplant recipients. Am J Transpl 15:2908–2920. https://doi.org/10.1111/ajt.13480CrossRef

Ng LG, Sutherland APR, Newton R et al (2004) B cell-activating factor belonging to the TNF family (BAFF)-R is the principal baff receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 173:807–817. https://doi.org/10.4049/JIMMUNOL.173.2.807CrossRefPubMed

Pelzl S, Opelz G, Daniel V et al (2003) Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 75:421–423. https://doi.org/10.1097/01.TP.0000044702.18327.66CrossRefPubMed

Pongpirul W, Chancharoenthana W, Pongpirul K et al (2018) B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients. Nephrology 23:169–174. https://doi.org/10.1111/nep.12972CrossRefPubMed

Sakai J, Akkoyunlu M (2017) The role of BAFF system molecules in host response to pathogens. Clin Microbiol Rev 30:991–1014. https://doi.org/10.1128/CMR.00046-17CrossRefPubMedPubMedCentral

Shimizu T, Toma H, Hayakawa N et al (2016) Clinical and pathological analyses of interstitial fibrosis and tubular atrophy cases after kidney transplantation. Nephrology 21:26–30. https://doi.org/10.1111/NEP.12766CrossRefPubMed

Slavcev A, Brozova J, Slatinska J et al (2016) Soluble BAFF cytokine levels and antibody-mediated rejection of the kidney allograft. Arch Immunol Ther Exp 64(suppl 1):47–53. https://doi.org/10.1007/s00005-016-0428-4CrossRef

Smulski CR, Kury P, Seidel LM et al (2017) BAFF- and TACI-dependent processing of BAFFR by ADAM proteases regulates the survival of B cells. Cell Rep 18:2189–2202. https://doi.org/10.1016/J.CELREP.2017.02.005CrossRefPubMed

Solgi G, Furst D, Mytilineos J et al (2012) Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Transpl Immunol 26:81–87. https://doi.org/10.1016/J.TRIM.2011.12.002CrossRefPubMed

Süsal C, Pelzl S, Döhler B, Opelz G (2002) Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13:1650–1656. https://doi.org/10.1097/01.ASN.0000014256.75920.5BCrossRefPubMed

Tai YT, Lin L, Xing L et al (2019) APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia 33:426–438. https://doi.org/10.1038/s41375-018-0242-6CrossRefPubMed

Thaler FS, Laurent SA, Huber M et al (2017) Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma. Neuro Oncol 19:1618–1627. https://doi.org/10.1093/NEUONC/NOX097CrossRefPubMedPubMedCentral

Thibault-Espitia A, Foucher Y, Danger R et al (2012) BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. Am J Transpl 12:2754–2762. https://doi.org/10.1111/j.1600-6143.2012.04194.xCrossRef

Wang D, Wu GJ, Wu WZ et al (2007) Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl Immunol 17:278–282. https://doi.org/10.1016/J.TRIM.2007.02.001CrossRefPubMed

Wang XZ, Wan Z, Xue WJ et al (2019) B-cell activating factor predicts acute rejection risk in kidney transplant recipients: a 6-month follow-up study. Front Immunol 10:1046. https://doi.org/10.3389/FIMMU.2019.01046/BIBTEXCrossRefPubMedPubMedCentral

Xu H, He X, Xu R (2018) B cell activating factor, renal allograft antibody-mediated rejection, and long-term outcome. J Immunol Res 2018:251801. https://doi.org/10.1155/2018/5251801CrossRef

Yu G, Boone T, Delaney J et al (2000) APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 1:252–256. https://doi.org/10.1038/79802CrossRefPubMed

Titel: Monitoring of Soluble Forms of BAFF System (BAFF, APRIL, sR-BAFF, sTACI and sBCMA) in Kidney Transplantation
verfasst von: Rafael Alfaro
Santiago Llorente
Pedro Martinez
Víctor Jimenez-Coll
Helios Martínez-Banaclocha
José Antonio Galián
Carmen Botella
María Rosa Moya-Quiles
Jesús de la Peña-Moral
Alfredo Minguela
Isabel Legaz
Manuel Muro
Publikationsdatum: 01.12.2022
Verlag: Springer International Publishing
Erschienen in: Archivum Immunologiae et Therapiae Experimentalis / Ausgabe 1/2022
Print ISSN: 0004-069X
Elektronische ISSN: 1661-4917
DOI: https://doi.org/10.1007/s00005-022-00659-4

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

What Has Immunology Brought to Periodontal Disease in Recent Years?

Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies

Bisphenol A: Potential Factor of Miscarriage in Women in the Context of the Phenomenon of Neutrophil Extracellular Traps

Transcriptome Studies in Lupus Nephritis

Effects of Local Nasal Immunotherapy with FIP-fve Peptide and Denatured Tyrophagus putrescentiae for Storage Mite-Induced Airway Inflammation

Angiotensin II Type 1 Receptor Antibodies Are Higher in Lupus Nephritis and Vasculitis than Other Glomerulonephritis Patients